ProMetic and Blue Blood of Taiwan form strategic alliance to develop plasma-derived drugs

13-Jun-2007

ProMetic BioTherapeutics, Inc., a subsidiary of ProMetic Life Sciences Inc. , and Blue Blood Biotech Corporation have formed a strategic alliance to develop drugs derived from human plasma utilizing ProMetic's proprietary manufacturing process.

The alliance between the two companies will initially target hyperimmune Cytomegalovirus (CMV), as well as two other high value therapeutics, with Taiwan and Southeast Asia as the primary markets. Although the financial details of the alliance were not disclosed, ProMetic and Blue Blood will share in the revenue derived from the sales of products.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances